These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 23630300

  • 1. Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol.
    Rickels MR, Liu C, Shlansky-Goldberg RD, Soleimanpour SA, Vivek K, Kamoun M, Min Z, Markmann E, Palangian M, Dalton-Bakes C, Fuller C, Chiou AJ, Barker CF, Luning Prak ET, Naji A.
    Diabetes; 2013 Aug; 62(8):2890-7. PubMed ID: 23630300
    [Abstract] [Full Text] [Related]

  • 2. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.
    Froud T, Baidal DA, Faradji R, Cure P, Mineo D, Selvaggi G, Kenyon NS, Ricordi C, Alejandro R.
    Transplantation; 2008 Dec 27; 86(12):1695-701. PubMed ID: 19104407
    [Abstract] [Full Text] [Related]

  • 3. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes.
    Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE.
    JAMA; 2005 Feb 16; 293(7):830-5. PubMed ID: 15713772
    [Abstract] [Full Text] [Related]

  • 4. Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes.
    Rickels MR, Kong SM, Fuller C, Dalton-Bakes C, Ferguson JF, Reilly MP, Teff KL, Naji A.
    J Clin Endocrinol Metab; 2013 Nov 16; 98(11):E1780-5. PubMed ID: 24085506
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
    Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM.
    Diabetes; 2001 Apr 16; 50(4):710-9. PubMed ID: 11289033
    [Abstract] [Full Text] [Related]

  • 6. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
    Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, Pileggi A, Poggioli R, Ichii H, Khan A, Ferreira JV, Pugliese A, Esquenazi VV, Kenyon NS, Alejandro R.
    Am J Transplant; 2005 Aug 16; 5(8):2037-46. PubMed ID: 15996257
    [Abstract] [Full Text] [Related]

  • 7. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL, Meloche RM, Thompson D, Shapiro RJ, Fung M, Ao Z, Ho S, He Z, Dai LJ, Young L, Blackburn L, Kozak S, Kim PT, Al-Adra D, Johnson JD, Liao YH, Elliott T, Verchere CB.
    Arch Surg; 2005 Aug 16; 140(8):735-44. PubMed ID: 16103282
    [Abstract] [Full Text] [Related]

  • 8. Primary graft function, metabolic control, and graft survival after islet transplantation.
    Vantyghem MC, Kerr-Conte J, Arnalsteen L, Sergent G, Defrance F, Gmyr V, Declerck N, Raverdy V, Vandewalle B, Pigny P, Noel C, Pattou F.
    Diabetes Care; 2009 Aug 16; 32(8):1473-8. PubMed ID: 19638525
    [Abstract] [Full Text] [Related]

  • 9. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.
    Roelen DL, Huurman VA, Hilbrands R, Gillard P, Duinkerken G, van der Meer-Prins PW, Versteeg-van der Voort Maarschalk MF, Mathieu C, Keymeulen B, Pipeleers DG, Roep BO, Claas FH.
    Clin Exp Immunol; 2009 Apr 16; 156(1):141-8. PubMed ID: 19161445
    [Abstract] [Full Text] [Related]

  • 10. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes.
    O'Connell PJ, Holmes-Walker DJ, Goodman D, Hawthorne WJ, Loudovaris T, Gunton JE, Thomas HE, Grey ST, Drogemuller CJ, Ward GM, Torpy DJ, Coates PT, Kay TW, Australian Islet Transplant Consortium.
    Am J Transplant; 2013 Jul 16; 13(7):1850-8. PubMed ID: 23668890
    [Abstract] [Full Text] [Related]

  • 11. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
    Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV.
    N Engl J Med; 2000 Jul 27; 343(4):230-8. PubMed ID: 10911004
    [Abstract] [Full Text] [Related]

  • 12. International trial of the Edmonton protocol for islet transplantation.
    Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR.
    N Engl J Med; 2006 Sep 28; 355(13):1318-30. PubMed ID: 17005949
    [Abstract] [Full Text] [Related]

  • 13. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients.
    Toso C, Morel P, Bucher P, Mathe Z, Demuylder-Mischler S, Bosco D, Berney T, Oberholzer J, Shapiro J, Oberholzer J, Philippe J.
    Transplantation; 2003 Oct 15; 76(7):1133-4. PubMed ID: 14557767
    [No Abstract] [Full Text] [Related]

  • 14. Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients.
    Lee D, Gillard P, Hilbrands R, Ling Z, Van de Velde U, Jacobs-Tulleneers-Thevissen D, Maleux G, Lapauw B, Crenier L, De Block C, Mathieu C, Pipeleers D, Keymeulen B.
    Transplantation; 2020 Oct 15; 104(10):e295-e302. PubMed ID: 32433237
    [Abstract] [Full Text] [Related]

  • 15. {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants.
    Rickels MR, Mueller R, Teff KL, Naji A.
    J Clin Endocrinol Metab; 2010 Mar 15; 95(3):1238-46. PubMed ID: 20097708
    [Abstract] [Full Text] [Related]

  • 16. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.
    Andres A, Toso C, Morel P, Demuylder-Mischler S, Bosco D, Baertschiger R, Pernin N, Bucher P, Majno PE, Bühler LH, Berney T.
    Transplant Proc; 2005 Mar 15; 37(2):1326-7. PubMed ID: 15848711
    [Abstract] [Full Text] [Related]

  • 17. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients.
    Koh A, Imes S, Kin T, Dinyari P, Malcolm A, Toso C, Shapiro AM, Senior P.
    Transplantation; 2010 Feb 15; 89(3):361-5. PubMed ID: 20145529
    [Abstract] [Full Text] [Related]

  • 18. Metabolic function of a suboptimal transplanted islet mass in nonhuman primates on rapamycin monotherapy.
    Soleimanpour SA, Hirshberg B, Bunnell DJ, Sumner AE, Ader M, Remaley AT, Rother KI, Rickels MR, Harlan DM.
    Cell Transplant; 2012 Feb 15; 21(6):1297-304. PubMed ID: 22080915
    [Abstract] [Full Text] [Related]

  • 19. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.
    Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, Mineo D, Baidal DA, Cure P, Ponte G, Mendez AJ, Selvaggi G, Ricordi C, Alejandro R.
    Transplantation; 2008 Dec 27; 86(12):1658-65. PubMed ID: 19104401
    [Abstract] [Full Text] [Related]

  • 20. Islet transplantation for brittle type 1 diabetes: the UIC protocol.
    Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, Qi M, Wang Y, Pallan P, Owens C, Bui J, West D, Kaplan B, Benedetti E, Oberholzer J.
    Am J Transplant; 2008 Jun 27; 8(6):1250-61. PubMed ID: 18444920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.